Risk of Myopericarditis following COVID-19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods

Katie A Sharff, David M Dancoes, Jodi L Longueil, Eric S Johnson, Paul F Lewis
doi: https://doi.org/10.1101/2021.12.21.21268209

Article Information

doi 
https://doi.org/10.1101/2021.12.21.21268209
History 
  • December 27, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Katie A Sharff, MDa,*,
  2. David M Dancoesb,
  3. Jodi L Longueil, PharmDc,
  4. Eric S Johnson, PhDb and
  5. Paul F Lewis, MD, MPHd
  1. aDepartment of Infectious Diseases, Kaiser Permanente Northwest, Portland, Oregon
  2. bDepartment of Analytics, Kaiser Permanente Northwest, Portland, Oregon
  3. cDivision of Pharmacy, Kaiser Permanente Northwest, Portland, Oregon
  4. dDepartment of Pediatrics, Kaiser Permanente Northwest, Portland Oregon
  1. ↵*Correspondence: Katie A. Sharff, Kaiser Permanente Northwest, Portland, Oregon, katie.a.sharff{at}kp.org
Back to top
Posted December 27, 2021.
Download PDF
Data/Code
Email
Risk of Myopericarditis following COVID-19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods
Katie A Sharff, David M Dancoes, Jodi L Longueil, Eric S Johnson, Paul F Lewis
medRxiv 2021.12.21.21268209; doi: https://doi.org/10.1101/2021.12.21.21268209
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area